OABI
OmniAb Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$384.18M
P/E Ratio
—
EPS
$-0.46
Beta
0.62
52W High
$2.73
52W Low
$1.22
50-Day MA
$1.69
200-Day MA
$1.75
Dividend Yield
—
Profit Margin
-187.60%
Forward P/E
—
PEG Ratio
—
About OmniAb Inc.
OmniAb Inc. is an innovative biotechnology company specializing in the development of fully human therapeutic antibodies via its proprietary OmniAb platform. This advanced technology enables the swift discovery and refinement of highly effective therapies aimed at addressing a wide spectrum of diseases. By leveraging strategic partnerships and collaborations, OmniAb aims to accelerate drug development processes and enhance access to groundbreaking treatments. With a seasoned leadership team and a robust pipeline of candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Fundamentals
| Revenue (TTM) | $28.94M |
| Gross Profit (TTM) | $28.62M |
| EBITDA | $-33.44M |
| Operating Margin | -54.30% |
| Return on Equity | -20.30% |
| Return on Assets | -11.30% |
| Revenue/Share (TTM) | $0.24 |
| Book Value | $1.81 |
| Price-to-Book | 1.46 |
| Price-to-Sales (TTM) | 13.28 |
| EV/Revenue | 12.21 |
| EV/EBITDA | -10.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 247.30% |
| Shares Outstanding | $144.97M |
| Float | $97.53M |
| % Insiders | 15.24% |
| % Institutions | 50.96% |
Historical Volatility
HV 10-Day
65.50%
HV 20-Day
70.87%
HV 30-Day
72.80%
HV 60-Day
67.25%
HV Rank
96.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($7.33 target)
7
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026